bemarituzumab, paclitaxel, ramucirumab

Phase 2

Amgen Inc. (AMGN)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Sep '27

AMGNPhase 2$219.9B

bemarituzumab, paclitaxel, ramucirumab Phase 2 Est. Readout

bemarituzumab, paclitaxel, ramucirumab• Metastatic Gastro-esophageal Adenocarcinoma126

Sep 2027~Estimated

CT.gov

00%

Competitive Landscape

0 competitors in Metastatic Gastro-esophageal Adenocarcinoma

View Full Landscape

Drug Information

Target Indication

Metastatic Gastro-esophageal Adenocarcinoma

Clinical Trial

NCT06680622

Last updated: 9/1/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AMGN

Amgen Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

Darbepoetin alphaPhase 3

Myelodysplastic Syndrome

IvabradinePhase 3

Postural Orthostatic Tachycardia Syndrome

Sorafenib (Nexavar, BAY43-9006)Phase 3

Thyroid Neoplasms

Darbepoetin alpha (Aranesp)Phase 3

Hematological Malignancies

chemotherapy with LMWH - enoxaparinPhase 3

Pancreatic Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts